IGM Biosciences is pioneering a new class of antibody medicines for the treatment of cancer and autoimmune and inflammatory diseases. Building upon the greater binding power provided by the naturally occurring IgM antibody structure, as compared with the commonly used IgG antibody structure, IGM has been able to create “super antibodies” with the potential to generate novel therapeutic options and hope for patients.
REIMAGINING
antibody medicines
Reimagining antibody medicines
We believe we have the world’s most advanced research and development program focused on engineered therapeutic IgM antibodies.
Using our expertise to expand upon and improve the inherent qualities of IgM antibodies and produce them at scale, we aim to develop a range of therapeutic antibodies for the treatment of cancer and autoimmune and inflammatory diseases.
Exploring scientific boundaries
By developing this new class of antibodies,
we have opened up new approaches to treating disease.
Make an impact at IGM
Help us bring a new class of antibody medicines to patients.
Recent News
August 14, 2024
May 8, 2024
April 17, 2024
Featured
Presentations at the 2024 American Association for Cancer Research Annual Meeting
IGM-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager Demonstrates Potent Efficacy on Myeloma Cells with an Improved Preclinical Safety Profile
64th American Society of Hematology (ASH) Annual Meeting and Exposition — December 10-13, 2022
Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-In-Class CD20xCD3 Bispecific IGM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies
64th American Society of Hematology (ASH) Annual Meeting and Exposition — December 10-13, 2022
